Arypiprazol – teoria i praktyka Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2022
Słowa kluczowe:
arypiprazol, schizofrenia, choroba afektywna dwubiegunowa, monoterapia, bezpieczeństwo
##plugins.themes.bootstrap3.article.main##
Abstrakt
Arypiprazol jest jednym z leków przeciwpsychotycznych II generacji, inaczej – atypowych, znanym od kilkunastu lat. Ma unikalny profil receptorowy względem pozostałych leków przeciwpsychotycznych, co znajduje odzwierciedlenie w jego efekcie terapeutycznym i profilu tolerancji. Działa jak antagonista w sytuacji nadmiaru dopaminy, natomiast przy jej niskich stężeniach eksponuje właściwości agonistyczne. Jak pokazują liczne badania, w zależności od dawki arypiprazol jest skuteczny w leczeniu schizofrenii i choroby afektywnej dwubiegunowej zarówno w okresie zaostrzenia, jak i w terapii podtrzymującej. Jest też lekiem często stosowanym w politerapii. Niniejszy artykuł dostarcza przeglądu informacji na temat zastosowania arypiprazolu w monoterapii, która powinna stać się rutynową praktyką w leczeniu zaburzeń psychicznych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Szulc, A. (2022). Arypiprazol – teoria i praktyka . Medycyna Faktów , 15(3(56), 368-374. https://doi.org/10.24292/01.MF.0322.16
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015; 29(9): 773-99.
2. Seelman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987; 1(2): 133-52.
3. Hart XM, Schmitz CN, Grunder G. Molecular Imaging of Dopamine Partial Antagonists in Humana: Implications for Clinical Practice. Front Psychiatry. 2022; 13: 832209.
4. Chrzanowski WK, Marcus RN, Torbeyns A et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259-66.
5. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635-47.
6. ABILIFY. Charakterystyka produktu leczniczego.
7. Szulc A, Więdlocha M, Marcinowicz P. Arypiprazol. Via Medica, Gdańsk 2018.
8. Sparshatt A, Taylor D, Patel MX et al. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447-56.
9. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003; 6: 325-37.
10. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394(10202): 939-51.
11. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta- analysis. Lancet. 2013; 382(9896): 951-62.
12. Ribeiro ELA, Mendonça Lima T, Vieira MEB et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018; 74: 1215-33.
13. Szulc A, Więdlocha M. Arypiprazol – częściowy agonizm, pełna skuteczność. Psychiatria. 2017; 14(1): 1-6.
14. Szulc A. Arypiprazol – monoterapia? Psychiatria. 2020; 17(1): 29-35.
15. Suppes T, Eudicone J, McQuade R et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. Affect Disord. 2008; 107(1-3): 145-54.
16. Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2013; (12): CD005000.
17. Muneer A. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus. 2016; 8(4): e562.
18. Li DJ, Tseng PT, Stubbs B et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79: 289-301.
19. Takeshima M. Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr. 2017; 22(2): 177-85.
20. Betzler F, Stöver LA, Sterzer P et al. Mixed states in bipolar disorder – changes in DSM-5 and current treatment recommendations. Int J Psychiatry Clin Pract. 2017; 21(4): 244-58.
21. Chakrabarty T, Keramatian K, Yatham LN. Treatment of Mixed Features in Bipolar disorder: An Updated Review. Cur Psych Rep. 2020; 22: 15-9.
22. Arypiprazol – charakterystyka produktu leczniczego FDA (access: 25.11.2016).
23. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. 2nd ed. Via Medica, Gdańsk 2015.
24. Poyurovsky M, Bergman J, Pashinian A et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol. 2014; 29(5): 296-8.
25. Citrome L, Eramo A, Francois C et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 3095-104.
26. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1386-92.
2. Seelman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987; 1(2): 133-52.
3. Hart XM, Schmitz CN, Grunder G. Molecular Imaging of Dopamine Partial Antagonists in Humana: Implications for Clinical Practice. Front Psychiatry. 2022; 13: 832209.
4. Chrzanowski WK, Marcus RN, Torbeyns A et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259-66.
5. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635-47.
6. ABILIFY. Charakterystyka produktu leczniczego.
7. Szulc A, Więdlocha M, Marcinowicz P. Arypiprazol. Via Medica, Gdańsk 2018.
8. Sparshatt A, Taylor D, Patel MX et al. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447-56.
9. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003; 6: 325-37.
10. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394(10202): 939-51.
11. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta- analysis. Lancet. 2013; 382(9896): 951-62.
12. Ribeiro ELA, Mendonça Lima T, Vieira MEB et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018; 74: 1215-33.
13. Szulc A, Więdlocha M. Arypiprazol – częściowy agonizm, pełna skuteczność. Psychiatria. 2017; 14(1): 1-6.
14. Szulc A. Arypiprazol – monoterapia? Psychiatria. 2020; 17(1): 29-35.
15. Suppes T, Eudicone J, McQuade R et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. Affect Disord. 2008; 107(1-3): 145-54.
16. Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2013; (12): CD005000.
17. Muneer A. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus. 2016; 8(4): e562.
18. Li DJ, Tseng PT, Stubbs B et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79: 289-301.
19. Takeshima M. Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr. 2017; 22(2): 177-85.
20. Betzler F, Stöver LA, Sterzer P et al. Mixed states in bipolar disorder – changes in DSM-5 and current treatment recommendations. Int J Psychiatry Clin Pract. 2017; 21(4): 244-58.
21. Chakrabarty T, Keramatian K, Yatham LN. Treatment of Mixed Features in Bipolar disorder: An Updated Review. Cur Psych Rep. 2020; 22: 15-9.
22. Arypiprazol – charakterystyka produktu leczniczego FDA (access: 25.11.2016).
23. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. 2nd ed. Via Medica, Gdańsk 2015.
24. Poyurovsky M, Bergman J, Pashinian A et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol. 2014; 29(5): 296-8.
25. Citrome L, Eramo A, Francois C et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 3095-104.
26. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1386-92.